PMID- 36415100 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20230602 IS - 2212-3970 (Electronic) IS - 1574-8928 (Print) IS - 1574-8928 (Linking) VI - 18 IP - 4 DP - 2023 TI - The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis. PG - 528-537 LID - 10.2174/1574892818666221122114753 [doi] AB - BACKGROUND: Thymic epithelial tumors (TETs) are rare thoracic malignancies with no standard second-line treatment. Tumor angiogenesis is closely associated with the pathogenesis and invasiveness of TETs. Anlotinib is a small-molecule multitarget tyrosine kinase inhibitor (TKI) which inhibits tumor angiogenesis and tumor cell proliferation. Published studies have demonstrated the promising clinical effect of multitarget TKIs sunitinib and lenvatinib in previously treated TETs. However, TKIs have a high incidence of adverse events (AEs). OBJECTIVE: In this study, we investigated the clinical efficacy and safety of anlotinib in previously treated TET patients. METHODS: We collected clinical data of 22 patients from Shandong Cancer Hospital and Institute between October 2018 and March 2022. These patients were diagnosed with advanced TETs and received at least the first-line (1st-line) treatment. We analyzed the clinical effects between anlotinib monotherapy and anlotinib combination therapy in the second-line (2nd-line) or anlotinib treatment in different lines. RESULTS: These 22 patients included 18 cases of thymic carcinoma (TC) and 4 cases of thymoma (T). 68.2% of patients were males, and the median age was 53 years. Fourteen patients (63.6%) received anlotinib monotherapy and 8 patients (36.4%) received anlotinib combination therapy. The objective response rate (ORR) was 9.1% in the overall patients. The median progression-free survival (PFS) in the overall population was 12 months (14 months for T and 9 months for TC), and the median overall survival (OS) was 24 months (survival was not reached for T and was 24 months for TC). The incidence of AEs was 50%, most of them were grades I and II, and the incidence of grades III and IV AEs was 9%. CONCLUSION: This is the first study reporting the clinical effect of anlotinib in previously treated TETs patients. The survival data indicate that the efficacy of anlotinib is superior to sunitinib and lenvatinib. Our results suggest that anlotinib is a promising treatment option for previously treated TET patients and its toxicity is tolerable. More research and patents are needed in the future to explore better options for the diagnosis and treatment of TETs. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Li, Shuo AU - Li S AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. FAU - Zhou, Haiyan AU - Zhou H AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China. FAU - Zhang, Xiqin AU - Zhang X AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China. FAU - Bu, Bing AU - Bu B AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China. FAU - Tao, Rongjie AU - Tao R AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China. FAU - Zhang, Hui AU - Zhang H AD - Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China. FAU - Yu, Jinming AU - Yu J AD - Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. LA - eng GR - ZR2019LZL015/Shandong University/ GR - 2018GSF118097/National Science Foundation of China, Shandong Province of China/ GR - 8150111724/National Natural Science Foundation of China (NSFC)/ PT - Journal Article PL - United Arab Emirates TA - Recent Pat Anticancer Drug Discov JT - Recent patents on anti-cancer drug discovery JID - 101266081 RN - V99T50803M (Sunitinib) RN - 0 (anlotinib) RN - EE083865G2 (lenvatinib) RN - Thymic epithelial tumor SB - IM MH - Male MH - Humans MH - Middle Aged MH - Female MH - Sunitinib MH - Retrospective Studies MH - *Patents as Topic MH - *Neoplasms, Glandular and Epithelial/drug therapy PMC - PMC10230606 OTO - NOTNLM OT - Thymic epithelial tumor OT - anlotinib OT - multi-line OT - second-line OT - thymic carcinoma OT - thymoma COIS- The authors declare no conflict of interest, financial or otherwise. EDAT- 2022/11/24 06:00 MHDA- 2023/03/28 06:00 PMCR- 2023/05/31 CRDT- 2022/11/23 01:03 PHST- 2022/05/27 00:00 [received] PHST- 2022/09/14 00:00 [revised] PHST- 2022/10/06 00:00 [accepted] PHST- 2022/11/24 06:00 [pubmed] PHST- 2023/03/28 06:00 [medline] PHST- 2022/11/23 01:03 [entrez] PHST- 2023/05/31 00:00 [pmc-release] AID - PRA-EPUB-127742 [pii] AID - PRA-18-528 [pii] AID - 10.2174/1574892818666221122114753 [doi] PST - ppublish SO - Recent Pat Anticancer Drug Discov. 2023;18(4):528-537. doi: 10.2174/1574892818666221122114753.